Hydroquinone Stabilizing Composition

The use of poloxamer micelles stabilizes hydroquinone, enhancing skin permeability and oxidative stability, addressing oxidative instability and toxicity issues in hydroquinone compositions for improved skin whitening.

JP7596012B2Active Publication Date: 2024-12-09LG HOUSEHOLD & HEALTH CARE LTD +1
View PDF 11 Cites 0 Cited by

Patent Information

Application Number
JP2023501400
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-05-26
Filing Date
2021-06-18
Publication Date
2024-12-09
Estimated Expiration
2041-06-18

AI Technical Summary

Technical Problem

Existing hydroquinone compositions face issues with oxidative instability, skin permeability, and side effects, limiting their effectiveness as a skin whitening agent due to oxidation and potential cytotoxicity.

Method used

A composition using hydroquinone or its derivatives stabilized by poloxamer micelles, formed through self-assembly, enhances skin permeability and oxidative stability, minimizing discoloration and toxicity.

Benefits of technology

The composition achieves high solubilized concentration and dissolution stability of hydroquinone, reducing oxidation-induced toxicity and improving skin whitening efficacy while maintaining stability against external stimuli.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007596012000006
    Figure 0007596012000006
  • Figure 0007596012000007
    Figure 0007596012000007
  • Figure 0007596012000008
    Figure 0007596012000008
Patent Text Reader

Abstract

The present invention provides a composition containing hydroquinone or a derivative thereof as an active ingredient, stabilized with a poloxamer. The composition of the present invention increases the solubilization concentration of hydroquinone or a derivative thereof, thereby maintaining high solubility stability without precipitation even at high concentrations in the aqueous phase. It also prevents oxidation caused by external stimuli such as heat, oxygen, or light, thereby increasing shelf life and preventing discoloration, thereby reducing toxicity and inflammatory responses due to hydroquinone oxidation products. Furthermore, the composition of the present invention enhances the skin permeability of hydroquinone or a derivative thereof through the use of micelles, thereby enhancing whitening efficacy, making it useful for whitening treatments containing hydroquinone or a derivative thereof as an active ingredient.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a composition containing hydroquinone or its derivatives as an active ingredient, and more particularly, to a composition that can maximize whitening effect by minimizing skin side effects and increasing skin permeability.

[0002] This application claims priority to Korean Patent Application No. 10-2020-0084277 filed on July 8, 2020, and Korean Patent Application No. 10-2021-0067884 filed on May 26, 2021, the entire contents of which are incorporated herein by reference in their entirety in the specification and drawings. [Background technology]

[0003] Skin is an important tissue that functions to protect the human body and is roughly divided into the epidermis, dermis, and subcutaneous tissue. Melanin produced by melanocytes in the basal layer of the epidermis absorbs light energy and protects the organs below the dermis from UV damage. However, when melanin is synthesized excessively due to increased exposure to UV rays caused by environmental pollution and aging, or when melanin accumulates due to improper keratinization, pigmentation is formed, forming age spots and freckles, and the skin becomes darker.

[0004] In order to prevent such pigmentation, kojic acid, vitamin C (L-ascorbic acid), glutathione, etc. have been commonly used in the field of conventional cosmetics. However, these do not have a significant whitening effect. Meanwhile, hydroquinone, unlike the above ingredients, has an excellent whitening effect, but has the problem of being easily discolored by oxidation due to air or light. Oxidized hydroquinone generates quinhydrone via benzoquinone (p-benzoquinone), which is known to induce cytotoxicity and have carcinogenic and allergy-inducing properties.

[0005] Due to these issues, hydroquinone is permitted only at restricted concentrations in each country, and traditionally, it has been packaged in a sealed, light-proof container to prevent oxidation of hydroquinone. However, after opening the product, exposure to oxygen and light is unavoidable. For this reason, methods have been reported to reduce the oxidation of hydroquinone by adjusting the pH to around 4 or by applying various antioxidants (e.g., ascorbic acid). However, skin allergies have been reported when using hydroquinone ointments containing ascorbic acid as an antioxidant, and discoloration of the antioxidant itself may be induced when Vitamin E or ascorbic acid is applied.

[0006] Meanwhile, a technique is known in which dimethyl isosorbide (DMI) is used as a skin permeation enhancer to increase the skin permeability of hydroquinone. However, this technique has a problem in that it is impossible to prevent discoloration of hydroquinone at high temperatures. Summary of the Invention [Problem to be solved by the invention]

[0007] Therefore, an object of the present invention is to provide a hydroquinone composition which not only improves skin permeability but also ensures the oxidative stability of hydroquinone.

[0008] Another object of the present invention is to provide a composition containing hydroquinone as an active ingredient, which ensures not only the skin permeability and oxidation stability but also formulation stability.

[0009] Another object of the present invention is to provide a composition having the above-mentioned advantages, which results in minimizing side effects on the skin and maximizing skin whitening effects. [Means for solving the problem]

[0010] In order to solve the above problems, the present invention provides a composition comprising hydroquinone or a derivative thereof as an active ingredient, and stabilizing the hydroquinone or a derivative thereof using a poloxamer.

[0011] Another aspect of the present invention provides a composition comprising hydroquinone or a derivative thereof as an active ingredient, stabilizing the hydroquinone or its derivative using a poloxamer, and using a mixture of two or more types of poloxamers to further improve the oxidative stability and formulation stability of the active ingredient.

[0012] The present inventors have confirmed that by forming micelles from poloxamers and locating hydroquinone or its derivatives inside or around the micelles, the content of hydroquinone or its derivatives can be increased and stabilized, as well as the skin permeability can be improved, thus completing the present invention. In addition, by forming a ternary mixture (hydroquinone or its derivatives and two poloxamers) using two or more poloxamers with different lengths of hydrophilic blocks, the stability of hydroquinone or its derivatives can be further improved, and gelation can be prevented even in an environment where the outside is a water phase, thereby improving the stability of the formulation, thus completing one aspect of the present invention. It is presumed that the ternary mixture of the present invention prevents gelation due to steric hindrance, and that the hydroquinone collection efficiency can be increased in the space formed by the entanglement of the hydrophilic blocks, but the present invention is not limited to such theoretical presumption.

[0013] Therefore, one aspect of the present invention provides a composition that forms micelles by self-assembly using one or more block copolymers poloxamer, and traps hydroquinone in the micelles to prevent discoloration due to oxidation or light, thereby minimizing side effects on the skin and increasing skin permeability. Another aspect of the present invention provides a composition that contains hydroquinone or a derivative thereof as an active ingredient, and contains one or more (preferably two or more) poloxamer micelles, and the external phase containing the micelles is an aqueous phase. Effect of the Invention

[0014] The present invention provides a composition containing hydroquinone or a derivative thereof, which can increase the solubilization concentration of hydroquinone or a derivative thereof, and can have high dissolution stability without precipitating even at high concentrations in the aqueous phase, and can increase storage stability by preventing oxidation reactions due to external stimuli such as heat, oxygen, or light, and can prevent discoloration, thereby reducing toxicity due to oxidation products of hydroquinone and reducing inflammatory reactions.In addition, the composition of the present invention can improve the skin permeability of hydroquinone or a derivative thereof by the micelle, and can enhance whitening efficacy, so it is useful for whitening improvement containing hydroquinone or a derivative thereof as an active ingredient. [Brief description of the drawings]

[0015] [Figure 1] FIG. 1 is a schematic diagram of a micelle that captures hydroquinone using poloxamer, a triblock copolymer consisting of a hydrophobic polyoxypropylene in the center and hydrophilic polyoxyethylene on both sides. [Diagram 2] 1 shows the results of an experiment evaluating the reduced cytotoxicity of stabilized hydroquinone. [Diagram 3] These are the experimental results of photographically evaluating the reduction in discoloration of stabilized hydroquinone. [Figure 4] 1 is an experimental result of the color difference degree of the reduction in discoloration of stabilized hydroquinone. [Diagram 5]This shows the results of applying Example 1 and Comparative Example 2 to the epidermis of a pig. [Figure 6] 1 shows the results of an experiment evaluating the effect of increasing the skin delivery efficiency of stabilized hydroquinone. [Figure 7] The results are shown in Table 3. Three days after Example 1, Comparative Example 1, and Comparative Example 2 were applied to 3D skin, the cross section was cut and the change in melanin was confirmed. [Figure 8] These are the results of an evaluation of the effect of the type of poloxamer on the stability and gelation of hydroquinone. [Figure 9] These are the results of evaluating the effect of poloxamer content on the harsh stability of hydroquinone. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] In the present invention, the hydroquinone or its derivative as the active ingredient may be at least one selected from the group consisting of hydroquinone, hydroquinone monobenzyl ether, hydroquinone monomethyl ether, and hydroquinone monoethyl ether, and preferably hydroquinone.

[0017] Hydroquinone or its derivatives are preferably contained in an amount of 0.1-10% by weight, more preferably 0.5-8% by weight, and more preferably 1-5% by weight, based on the total weight of the composition. If the amount is 10% by weight or more, hydroquinone that is not trapped in the micelles may oxidize or may be present outside, causing discoloration.

[0018] In the present invention, examples of poloxamers that can be used as ternary copolymers composed of PEO-PPO-PEO include poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407 (the first two digits of the three-digit number included in the name of poloxamer represent the approximate molecular weight (g / mol) of PPO divided by 100, and the last digit represents the percentage of PEO content in the poloxamer divided by 10).

[0019] In the present invention, the term "about" or "approximately" means ±20% of the numerical value, and preferably ±10% of the numerical value.

[0020] In the present invention, the poloxamer is preferably contained in an amount of 0.1 to 40% by weight based on the total weight of the composition. For example, 0.1 to 20% by weight, more preferably 0.5 to 10% by weight, and even more preferably 2.5 to 5% by weight based on the total weight of the composition may be used. However, the minimum content of poloxamer must be such that it can form micelles. If the content of poloxamer is too low, micelles sufficient to capture hydroquinone cannot be formed, and if the content is too high, gelation problems may occur.

[0021] In the case of the poloxamer of the present invention, unlike liposomes and nanoemulsions that require a separate process such as high-pressure emulsification, no separate process is required, i.e., it can be produced by self-assembly, and therefore it can be said to be a more efficient method of solubilization and micelle formation in terms of productivity.

[0022] Preferably, the composition according to one embodiment of the present invention contains two or more poloxamers as the poloxamer, and one of the two poloxamers (first poloxamer) is a poloxamer having a PPO molecular weight of about 1200 to 1800 g / mol and a PEO content percentage of about 30 to 80%, preferably 40 to 80% (e.g., poloxamer 188, 185, 124, 184, etc.), and the other poloxamer (second poloxamer) is a poloxamer having a PPO molecular weight of about 3000 to 4500 g / mol and a PEO content percentage of about 30 to 80%, preferably 40 to 80% (e.g., poloxamer 338, 407, 334, 335, etc.). When two poloxamers having different physical properties are mixed and used, it is more preferable in terms of preventing gelation as well as preventing oxidation of hydroquinone.

[0023] More preferably, the composition according to one embodiment of the present invention includes a poloxamer having a polyoxypropylene molecular weight of about 1800 g / mol and a polyoxyethylene content of about 80% by weight (e.g., poloxamer 188), a poloxamer having a polyoxypropylene molecular weight of about 3300 g / mol and a polyoxyethylene content of about 80% by weight (e.g., poloxamer 338), and a poloxamer having a polyoxypropylene molecular weight of about 4000 g / mol and a polyoxyethylene content of about 70% by weight (e.g., poloxamer 407). That is, a preferred composition according to one embodiment of the present invention includes a combination of poloxamers 188 and 338, a combination of poloxamers 188 and 407, or a combination of poloxamers 188, 338, and 407.

[0024] When the first and second poloxamers are used, the weight ratio of the mixture thereof may be 1:0.1-10, preferably 1:0.2-5, and more preferably 1:0.8-1.2.

[0025] In another embodiment of the present invention, when a combination of poloxamers is used, for example, the first poloxamer and the second poloxamer may be mixed in a weight ratio of 1:0.01 to 1. That is, it is more preferable for the first poloxamer to be used in the same amount or in a relatively small amount for various purposes of the present invention.

[0026] The composition according to the present invention may further contain an antioxidant to further improve the stability of hydroquinone or its derivatives. The antioxidant is used to further improve the storage stability of hydroquinone trapped in micelles, and may be one or more of sodium bisulfite, sodium sulfite, vitamin C and its derivatives, vitamin E and its derivatives, dibutylhydroxytoluene (BHT), ethylenediaminetetraacetic acid (EDTA), and glutathione. If used, the antioxidant is preferably contained in an amount of 0.05 to 15% by weight, more preferably 0.1 to 10% by weight, based on the total weight of the composition. An excessive amount of antioxidant may induce discoloration of the antioxidant itself or cause phase separation of micelles due to block copolymers. However, the antioxidant contained in the composition of the present invention is used to further improve the stability of hydroquinone or its derivatives, and the addition of the antioxidant is optional.

[0027] In addition to the above components, the composition according to the present invention contains water and a hydrophilic solvent as substances for dissolving hydroquinone or its derivatives, and such components may be contained in the remaining amount excluding the hydroquinone or its derivatives, poloxamer, and antioxidant.

[0028] The hydrophilic solvent may be a polyhydric alcohol or a volatile organic solvent. Specific examples include, but are not limited to, polyethylene glycol, propylene glycol, dipropylene glycol, glycerin, 1,3-butanediol, isopropyl alcohol, and ethanol. Preferably, isopropyl alcohol and / or ethanol may be used, and the hydrophilic solvent may be used in an amount of 5 to 50% by weight based on the total weight of the composition. The use of a hydrophilic solvent is not essential in the present invention, but when used, it can increase the storage stability of hydroquinone or its derivatives and make it easier to form micelles.

[0029] The composition according to the present invention may be a liquid composition having an aqueous phase on the outside, but may also be a liquid composition that has been solidified or powdered by freeze-drying or spray-drying. Since such solidified or powdered compositions are dispersed in an aqueous phase before use, the formulation stability of the composition of the present invention is important even for such solid compositions.

[0030] The composition of the present invention contains hydroquinone or its derivatives as an active ingredient, and therefore can be a composition for improving skin whitening. In another embodiment of the present invention, the composition of the present invention is a composition for application to the skin. The composition of the present invention can be a pharmaceutical composition or a cosmetic composition.

[0031] The composition of the present invention may be prepared as a cosmetic or pharmaceutical composition by a conventional method used in the technical fields of cosmetics or medicines, etc. The composition of the present invention may be formulated in various forms such as lotion, serum, gel, lotion, cream, powder, patch, etc., and may provide whitening effects and efficacy when applied to the skin.

[0032] Preferably, all of the ingredients described in the present invention do not exceed the maximum use values ​​stipulated in the relevant laws, regulations, and standards of Korea, China, the United States, Europe, Japan, etc. (e.g., Regulations on Cosmetic Safety Standards (Korea), Cosmetic Safety Technical Standards (China), Hygiene Standards (China)), etc. That is, preferably, the cosmetic, pharmaceutical or personal care composition according to the present invention contains the ingredients according to the present invention within the content limits permitted by the relevant laws, regulations and standards of each country.

[0033] The present invention will be described in detail below with reference to examples to aid in understanding the present invention. However, the embodiments according to the present invention may be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following examples. The embodiments of the present invention are provided to more completely explain the present invention to those having average knowledge in the field to which the present invention pertains. EXAMPLES

[0034] Production or preparation of Example 1 and Comparative Examples 1 and 2 First, Example 1 according to the present invention, Comparative Example 1 and Comparative Example 2 were prepared according to the compositions shown in Table 1 below.

[0035] [Table 1]

[0036] Example 1 is a hydroquinone composition trapped in a block copolymer. Comparative Example 1 is a hydroquinone composition not trapped in a block copolymer. Comparative Example 2 is a composition in which the non-trapped hydroquinone composition was allowed to discolor at 50° C. for 12 weeks.

[0037] Specifically, it was prepared as follows. A certain amount of distilled water was kept at 50-60°C and block copolymer 1 was mixed in the ratio shown in Table 1. The mixture was stirred at 1000 rpm until block copolymer 1 was completely dissolved, and then cooled to a temperature of 10°C. Block copolymer 2 was gradually added to the cooled solution, and stirred at room temperature to form micelles. After that, air bubbles were removed using a vacuum pump, and an antioxidant and a hydrophilic solvent were added at room temperature and mixed by stirring. Hydroquinone was then added, and the mixture was stirred at 1200 rpm to capture hydroquinone in micelles (see Figure 1).

[0038] In Comparative Examples 1 and 2, the hydrophilic solvent and hydroquinone were mixed in the ratio shown in Table 1 at room temperature at 1000 rpm without adding the block copolymer.

[0039] A commercially available cream containing hydroquinone was used in Comparative Examples 3 and 4. Comparative Examples 2 and 4 were used after being kept at 50°C for 12 weeks to allow oxidation in order to confirm the cytotoxic effect due to oxidation of hydroquinone.

[0040] Test Example 1: Cytotoxicity measurement of stabilized hydroquinone The compositions of Example 1 and Comparative Examples 1 to 4 were added to the culture medium of mouse melanoma cells (B-16 mouse melanoma cells), and the cytotoxicity at the same concentration was measured using a CCK-8 kit (Cell Counting Kit-8; Dojindo Co., Ltd., Japan). B16 cells were dispensed into a 96-well cell culture plate and treated so that the hydroquinone concentrations in the composition were 0, 0.6, 1.26, 2.5, 5, 10, 20, 40, and 80 μg / ml. After 48 hours, a CCK-8 solution was added. After 1 hour, the absorbance of the cell culture medium was measured at 405 nm to measure the cytotoxicity. The results are shown in FIG. 2.

[0041] As shown in FIG. 2, when the viability of the untreated control cell group was taken as 100%, hydroquinone captured in micelles using poloxamer (Example 1) showed a cell viability of 50% at a concentration of 40 μg / ml. On the other hand, hydroquinone dissolved in an aqueous phase not containing poloxamer (Comparative Examples 1 and 2) showed a cell viability of 40% or less at a concentration of 10 μg / ml. In addition, when a commercially available hydroquinone cream was oxidized at 50° C. and discolored (Comparative Example 4), it showed a cell viability of 50% at a concentration of 10 μg / ml. These results suggest that hydroquinone captured in micelles using the poloxamer of the present invention has a toxicity reducing effect on melanocytes.

[0042] Test Example 2: Measurement of the degree of discoloration of stabilized hydroquinone The storage stability of the compositions of Example 1 and Comparative Example 1 was confirmed. The test samples were kept at 50°C for 12 weeks, and then the color difference was calculated. 100 μl of each composition before (0 week) and after (12 weeks) storage at 50°C was placed in a white opaque 96-well plate, and the L value (lightness), a value (redness), and b value (yellowness) were measured three times using a Chromameter CR-400 (Minolta, Japan). The overall color difference was shown as the value of number 1 below. The base value for comparing the color difference was based on a standard plate containing the same amount of water, which is the solvent in which hydroquinone was dissolved. The results are shown in Figures 3 and 4.

number

[0043] As shown in Figures 3 and 4, after 12 weeks at 50°C, the untrapped hydroquinone of Comparative Example 1 showed a high color difference index change of 42. On the other hand, the hydroquinone trapped by the poloxamer of Example 1 showed a color difference index change of 6, which was similar to the value at week 0 of Comparative Example 1. This suggests that the storage stability can be improved by trapping hydroquinone in micelles using the poloxamer of the present invention.

[0044] Test Example 3. Evaluation of the ability of stabilized hydroquinone to be delivered to the skin The dermal delivery ability of the compositions of Example 1 and Comparative Example 1 was evaluated. A percutaneous absorption experiment was performed on the test samples using porcine skin. The receptor of a Franz diffusion cell was filled with 50% ethanol, and the epidermis of the pig was placed between the donor and the receptor so that it faced upward (donor side) and the dermis faced downward (receptor side). 0.1 ml of the compositions of Example 1 and Comparative Example 1 was applied to the skin and spread evenly. After that, the skin was placed in a thermo-hygrostat for 18 hours, and the skin tissue was collected. Only the skin tissue exposed to the composition was used and divided into the stratum corneum, epidermis, and dermis layers for analysis. The stratum corneum was measured using a D-Squame standard sampling disc. The remaining pig skin was heated at 70℃ for 15 seconds, then separated into epidermis and dermis layers, and the hydroquinone contained in each skin layer was dissolved in 50% ethanol. The results are shown in Figures 5 and 6.

[0045] 6, the hydroquinone trapped by the two types of block copolymers of Example 1 exhibited a skin permeability rate three times higher in the stratum corneum, epidermis, and dermis layers than that of Comparative Example 1. This suggests that the poloxamer micelles trapping hydroquinone according to the present invention can also enhance the delivery efficiency of hydroquinone to the skin.

[0046] Test Example 4. Evaluation of whitening and inflammation of stabilized hydroquinone on artificial skin To compare the whitening efficacy of Example 1 and Comparative Examples 1 and 2, a 3D artificial skin (Tego Science, Korea) consisting of epidermis and melanocytes was used. The artificial skin was exposed to UVB 50 mJ / cm 2After treatment with 1000 ml of 1000 ml of 1000 ml of each composition, 25 μl of each composition was applied to the artificial skin. After culturing for 3 days, the 3D skin was cut out with a paraffin block to measure the whitening efficacy, and the culture medium was used to evaluate inflammation. The whitening efficacy was evaluated from the change in the amount of melanin. Melanin was stained using Fontana-Masson staining, and after imaging under a microscope at 40x magnification, the amount of melanin was quantified using the ImageJ program. For the inflammation evaluation, the amount of interleukin 1a, an inflammatory secretory factor, was measured by measuring the amount of interleukin 1a secreted in the culture medium using an ELISA kit (R&D System, USA). The melanin formation inhibition efficacy and inflammation evaluation results in the 3D artificial skin are shown in Table 2 and Figure 7.

[0047] [Table 2]

[0048] As shown in Table 2 and Figure 7, the pigmentation inhibition efficacy was about 39% and 15% in Comparative Example 1, in which untrapped hydroquinone was applied, and Comparative Example 2, in which hydroquinone that had been kept at 50 ° C and discolored was applied, respectively, while Example 1, in which hydroquinone was trapped and stabilized with a block copolymer, showed a high pigmentation inhibition efficacy of 56%. In addition, the results of interleukin 1a, an inflammatory factor, were reduced by 34% in the case of stabilized hydroquinone. This suggests that hydroquinone stabilized in micelles using the poloxamer of the present invention can increase the skin whitening efficacy and reduce side effects such as inflammation.

[0049] Evaluating the impact of different poloxamer types Various poloxamer-containing compositions were prepared according to the formulations in Table 3 below in the same manner as in Example 1.

[0050] [Table 3]

[0051] After that, after leaving it at room temperature for 14 days, the presence or absence of discoloration and the degree of gelation were evaluated, and the results are shown in Figure 8. As shown in Figure 8, discoloration was the least when poloxamer 188 was used as the first poloxamer and mixed with 338 or 407 as the second poloxamer. In addition, when poloxamer 407 was used alone or mixed with 338, it was undesirable in terms of solubilization due to gelation.

[0052] Evaluation of the effect of poloxamer content As shown in Table 4 below, the formulation was the same as in Example 1, but the total poloxamer content was changed to 0-8%, and the weight ratio of the first poloxamer (Poloxamer 188) and the second poloxamer (Poloxamer 338) was maintained at 1:1.

[0053] [Table 4]

[0054] The stability over time was then observed under somewhat harsh conditions at 60°C, and the results are shown in Figure 9. As shown in Figure 9, 2.5-6 wt% poloxamer was stable up to 6 weeks, and the stability of hydroquinone was even better when 2.5-5 wt% poloxamer was used up to 12 weeks or more. However, these results were the result of harsh conditions, and at room temperature, other contents were also able to achieve sufficient stability for distribution.

Claims

1. Contains hydroquinone or its derivatives as an active ingredient. the derivative is hydroquinone monobenzyl ether, hydroquinone monomethyl ether, hydroquinone monoethyl ether or a mixture thereof, Poloxamer is used to stabilize hydroquinone or its derivatives, The poloxamer is a combination of a first poloxamer having a PPO molecular weight of 1200-1800 g / mol and a PEO content percentage of 30-80% and a second poloxamer having a PPO molecular weight of 3000-4500 g / mol and a PEO content percentage of 30-80%, The hydroquinone or its derivative is contained in an amount of 0.5 to 8% by weight based on the total weight of the composition, and The composition, wherein the poloxamer is contained in an amount of 0.1 to 20% by weight based on the total weight of the composition.

2. 2. The composition of claim 1, wherein the first poloxamer is poloxamer 188 and the second poloxamer is poloxamer 338, poloxamer 407, or a mixture thereof.

3. The composition of claim 1 or 2, wherein the composition comprises poloxamer micelles and the external phase in which the micelles are contained is an aqueous phase.

4. The composition according to claim 1 or 2, which is for improving skin whitening.

5. The composition of claim 1 or 2, further comprising an antioxidant.

Citation Information

Patent Citations

  • Whitening and skin care body lotion containing almond essential oil

    CN105997698A

  • Ylang-ylang essential oil containing lotion capable of whitening and caring skin

    CN106038391A

  • Water-soluble whitening composite formula and preparation method and application thereof

    CN108578261A

  • External preparation for skin

    JP1986227516A

  • Chitosan-coated nanocapsules and their uses

    JP2022514679A